Pathodynamics develops precision oncology reporting technology that utilizes artificial intelligence and molecular simulation to predict the functional effects of genetic variants. This enables oncologists to select the most effective drug based on a patient's genetic profile, improving treatment outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Oncologists face challenges in interpreting the functional effects of genetic variants in cancer patients, hindering their ability to select the most effective targeted therapies. The lack of precise information on how specific mutations impact drug response can lead to suboptimal treatment decisions and poorer patient outcomes.
Solution
Pathodynamics offers precision oncology reporting technology that leverages artificial intelligence and molecular simulation to predict the functional effects of genetic variants. By analyzing a patient's unique genetic profile, the platform provides oncologists with actionable insights into the likely response to various drugs. This enables clinicians to make more informed treatment choices, maximizing the potential for positive outcomes and minimizing the risk of ineffective therapies. The technology aims to bridge the gap between genomic data and clinical decision-making in oncology.
Target Audience
The primary target audience includes oncologists, molecular pathologists, and other healthcare professionals involved in cancer diagnosis and treatment who seek to leverage genomic information for personalized therapy selection.
Features
- AI-powered analysis of genetic variants to predict their functional impact on drug response.
- Molecular simulation techniques to model the effects of mutations at the protein level.
- Comprehensive reports summarizing the predicted efficacy of different drugs based on the patient's genetic profile.
- Integration with existing oncology workflows and electronic health record systems.
- Continuous updates with the latest scientific literature and drug information.